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Abstract
Background: Ipilimumab has shown long-term overall survival (OS) in patients with advanced melanoma in clinical
trials, but robust real-world evidence is lacking. We present long-term outcomes from the IMAGE study
(NCT01511913) in patients receiving ipilimumab and/or non-ipilimumab (any approved treatment other than
ipilimumab) systemic therapies.
Methods: IMAGE was a multinational, prospective, observational study assessing adult patients with advanced
melanoma treated with ipilimumab or non-ipilimumab systemic therapies between June 2012 and March 2015
with ≥3 years of follow-up. Adjusted OS curves based on multivariate Cox regression models included covariate
effects. Safety and patient-reported outcomes were assessed.
Results: Among 1356 patients, 1094 (81%) received ipilimumab and 262 (19%) received non-ipilimumab index therapy
(systemic therapy [chemotherapy, anti–programmed death 1 antibodies, or BRAF ± MEK inhibitors], radiotherapy, and
radiosurgery). In the overall population, median age was 64 years, 60% were male, 78% were from Europe, and 78%
had received previous treatment for advanced melanoma. In the ipilimumab-treated cohort, 780 (71%) patients did not
receive subsequent therapy (IPI-noOther) and 314 (29%) received subsequent non-ipilimumab therapy (IPI-Other) on
study. In the non-ipilimumab–treated cohort, 205 (78%) patients remained on or received other subsequent non-
ipilimumab therapy (Other-Other) and 57 (22%) received subsequent ipilimumab therapy (Other-IPI) on study. Among
1151 patients who received ipilimumab at any time during the study (IPI-noOther, IPI-Other, and Other-IPI), 296 (26%)
reported CTCAE grade≥ 3 treatment-related adverse events, most occurring in year 1. Ipilimumab-treated and non-
ipilimumab–treated patients who switched therapy (IPI-Other and Other-IPI) had longer OS than those who did not
switch (IPI-noOther and Other-Other). Patients with prior therapy who did not switch therapy (IPI-noOther and Other-
Other) showed similar OS. In treatment-naive patients, those in the IPI-noOther group tended to have longer OS than
those in the Other-Other group. Patient-reported outcomes were similar between treatment cohorts.
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Conclusions: With long-term follow-up (≥ 3 years), safety and OS in this real-world population of patients treated with
ipilimumab 3mg/kg were consistent with those reported in clinical trials. Patient-reported quality of life was
maintained over the study period. OS analysis across both pretreated and treatment-naive patients suggested a
beneficial role of ipilimumab early in treatment.
Trial registration: ClinicalTrials.gov, NCT01511913. Registered January 19, 2012 – Retrospectively registered,
https://clinicaltrials.gov/ct2/show/NCT01511913
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Background
According to the World Health Organization, ap-
proximately 132,000 new cases of melanoma are di-
agnosed worldwide each year [1]. It was estimated
that 100,350 new cases of melanoma would be diag-
nosed and 6850 people would die from the disease
in the United States in 2020 [1]. However, recent
data have shown that mortality rates have decreased
significantly in both males (with an annual percent-
age decrease of 6.9% from 2013 to 2016) and females
(with an annual percentage decrease of 9.3% from
2014 to 2016) diagnosed with melanoma of the skin
[2]. Treatment options for patients with unresectable
or metastatic (advanced) melanoma have evolved
from chemotherapy and cytokine-based therapy to
immunotherapy and targeted therapy in the past
decade [3]. In 2011, ipilimumab, an anti–cytotoxic
T-lymphocyte antigen 4 (anti–CTLA-4) antibody,
became the first approved immune checkpoint in-
hibitor after demonstrating significant improvement
in overall survival (OS) in patients with advanced
melanoma in randomised clinical trials [4–6]. Subse-
quently, anti–programmed death 1 (anti–PD-1) anti-
bodies (nivolumab and pembrolizumab) as well as
BRAF targeted therapies (vemurafenib ± cobimetinib,
dabrafenib ± trametinib, and encorafenib ± binimeti-
nib) were approved, radically improving outcomes for
patients with advanced melanoma [3, 7]. More recently,
nivolumab, pembrolizumab, and dabrafenib ± trametinib
have shown benefits in recurrence-free survival as adjuvant
treatment for high-risk resected melanoma [8].
Long-term survival has been reported in patients with
advanced melanoma treated with ipilimumab in phase II
and III clinical trials [9, 10]. A pooled analysis of 10
prospective and 2 retrospective studies of ipilimumab
demonstrated 3-year OS of 22% for all patients, 20% in
previously treated patients, and 26% in treatment-naive
patients [11]. Any-grade and grade 3/4 treatment-related
adverse events (TRAEs; according to National Cancer
Institute Common Terminology Criteria for Adverse
Events [CTCAE]) were reported in 80 and 23% of
patients, respectively [4]. Although efficacy and safety
results from randomised controlled trials of ipilimumab
are available, data from long-term real-world studies are
lacking. Real-world studies are being increasingly used
to complement results from clinical trials as they repre-
sent patients who are diagnosed and treated routinely,
including those who did not meet the selection criteria
for registration into randomised controlled trials (e.g.,
patients with Eastern Cooperative Oncology Group
performance status [ECOG PS] ≥ 2 or active/untreated
brain metastases) [12, 13]. Since the introduction of
anti–PD-1 antibodies, which have shown superior
first-line efficacy compared with ipilimumab [14, 15],
ipilimumab has been less commonly used as first-line
monotherapy. However, it is still used in combination
with nivolumab as first-line therapy in patients with
advanced melanoma [14] and as subsequent therapy
in patients with disease progression after single-agent
anti–PD-1 treatment [16].
IMAGE (ipilimumab: management of advanced melan-
oma in real practice; NCT01511913) is a multinational
observational study evaluating real-world treatment and
outcomes for patients with advanced melanoma. We
have previously published results of the retrospective
IMAGE study group [17], which provided insights into
patient care for advanced melanoma in the era before
ipilimumab was available. Here, we present results of the
prospective study group in which patients received
ipilimumab or non-ipilimumab systemic therapies. We
report the estimated incidence and severity of TRAEs in
patients treated with ipilimumab in the postapproval
setting using CTCAE criteria. We also describe OS in
the overall patient population, in previously treated
patients, and in treatment-naive patients treated with
ipilimumab or non-ipilimumab therapies. In addition,
we assess long-term quality of life (QoL) in the overall
patient population.
Methods
Patients and study design
IMAGE is a phase IV, multinational observational study
that recruited patients with advanced melanoma. The
study included retrospective and prospective groups.
The retrospective group consisted of patients with ad-
vanced melanoma who were treated with non-
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ipilimumab therapy within the 3 years prior to the ap-
proval of ipilimumab [17], whereas the prospective
group consisted of patients who were enrolled once
ipilimumab was approved and available for routine use.
Results of the prospective group are reported here. In
the prospective group, eligible patients were recruited
from 200 sites across 15 countries (Argentina, Australia,
Austria, Belgium, Canada, France, Germany, Greece,
Ireland, Israel, Poland, Spain, Switzerland, the United
Kingdom, and the United States). Patients were enrolled
over a period of approximately 30 months (June 2012 to
March 2015) and followed for a minimum of 3 years
(Additional file 1: Fig. A.1) or until loss to follow-up,
withdrawal of consent, or death. Enrollment began once
ipilimumab was approved in each country and available
for treatment in patients with advanced melanoma. This
study included two prospective groups: patients who re-
ceived ipilimumab as the index therapy (ipilimumab-
treated group) and those who received any approved
treatment other than ipilimumab as the index therapy
(non-ipilimumab–treated group). Ipilimumab was admin-
istered at 3 mg/kg by intravenous infusion for 90min
every 3 weeks for 4 doses or until disease progression,
unacceptable toxicity, or withdrawal of consent. Radio-
therapy was allowed with ipilimumab as a concomitant
therapy. Non-ipilimumab therapies included systemic
therapy (chemotherapy, anti–PD-1 antibodies, or BRAF ±
MEK inhibitors), radiotherapy, and radiosurgery.
Patients included in this study were adults (≥ 18 years
of age at study entry) who were diagnosed with and
treated for advanced melanoma by a health care provider
(community-based, office-based, hospital-based, or
academic setting). Patients who participated in another
clinical trial evaluating therapy for any cancer (including
advanced melanoma) or received therapy for a primary
cancer other than melanoma were excluded.
This study was approved by the institutional review
board/ethics committee at each participating centre
(Additional file 2) and was conducted in accordance
with the Declaration of Helsinki and International
Society for Pharmacoepidemiology Guidelines for Good
Epidemiology Practices. Patients generally provided
written consent for enrollment, but they could have
provided verbal consent documented by the site staff if
in accordance with local regulations and the institutional
review board/ethics committee.
Analysis populations
Patients who received ipilimumab or non-ipilimumab
therapy as index therapy were further divided into the
following groups: IPI-noOther, ipilimumab-treated patients
(with or without concomitant radiotherapy) who did not
receive subsequent systemic therapy during the study
period; IPI-Other, ipilimumab-treated patients who re-
ceived subsequent systemic non-ipilimumab therapy during
the study period; Other-Other, non-ipilimumab–treated
patients who remained on non-ipilimumab index therapy
or received other subsequent systemic non-ipilimumab
therapy during the study period; and Other-IPI, non-ipili-
mumab–treated patients who received subsequent sys-
temic ipilimumab therapy during the study period
(Fig. 1).
Safety analysis was conducted in patients who
received ipilimumab therapy (as index therapy or
subsequent therapy) at any time during the study
period (IPI-noOther, IPI-Other, and Other-IPI) (Fig. 1).
TRAEs were not reported in patients who did not receive
Fig. 1 Patient disposition. IPI ipilimumab
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ipilimumab during the study period. Effectiveness
and QoL assessments were conducted in all four
subgroups of patients.
Data collection
Data on patient demographics, baseline characteristics,
subsequent systemic therapy, and incidence of adverse
events were collected from electronic case report forms.
Safety data included TRAEs (non-serious and serious),
immune-related adverse events, and TRAEs leading to
discontinuation or death. A serious adverse event
included any medical occurrence that resulted in death,
a life-threatening condition, hospitalisation or prolonga-
tion of existing hospitalisation, persistent or significant
disability/incapacity, or a congenital anomaly or medical
event that led to these events. Early-onset adverse events
were defined as adverse events occurring between the
first dose and 90 days after the last dose of ipilimumab
therapy. Late-onset adverse events were defined as
adverse events occurring 90 days after the last dose of
ipilimumab [18]. The severity of adverse events was
graded according to CTCAE v3.0.
Effectiveness was assessed using 3-year OS rates and
tumor response. In this study, tumor response was based
on the last tumor assessment recorded with a non-
missing assessment date during the on-study period and
was determined by investigators using various response
criteria (the World Health Organization criteria, Response
Evaluation Criteria in Solid Tumors, or other response
criteria).
For QoL assessments, data were collected from patient-
reported questionnaires via electronic case report forms.
Patients completed the European Organisation for Research
and Treatment of Cancer (EORTC) QLQ-C30 question-
naire every 3months throughout the study period. The
EORTC QLQ-C30 is a 30-item, self-completed, multidi-
mensional, cancer-specific QoL questionnaire comprising a
global health status/QoL scale, three symptom scales, six
single-item scales, and five functional scales [19]. EORTC
QLQ-C30 scores were scaled from 0 to 100, with higher
scores representing higher global health status, greater
symptom/financial burden, and higher level of functioning.
A change of 10 points was considered a clinically meaning-
ful difference [20]. Completion rates were calculated from
the number of questionnaires returned from eligible
patients. Mean changes in patient-reported outcome scores
from baseline were evaluated descriptively for each scale;
interpretations were drawn from time points that had ≥10
patients completing assessments per treatment group.
Statistical analysis
Patient demographics and baseline characteristics
were reported using descriptive statistics, including
median, minimum, and maximum for continuous
variables, and count and percentage for categorical
variables. Descriptive data were provided for TRAEs
that occurred in patients treated with ipilimumab
therapy at any time during the study period. Given
the unique safety profile of ipilimumab related to its
distinct mechanism of action, no safety comparisons
were made between ipilimumab-treated and non-
ipilimumab–treated patients. Incidence rates for
TRAEs were calculated by dividing the number of
events by the overall total exposure during the speci-
fied time at risk. Confidence intervals (CIs) were cal-
culated for incidence rates.
OS probabilities were estimated using the Kaplan–
Meier product-limit method and adjusted based on
multivariate Cox regression models that included covari-
ate effects. Among a total of 25 covariates, 6 were
selected based on a stepwise Cox regression model
(Additional file 1: Table A.1). These covariates were
ECOG PS at study entry, lactate dehydrogenase (LDH)
status, EORTC QLQ-C30 QoL (based on overall health
status score and QoL in the past week), prior therapy,
sex, and Work Productivity and Activity Questionnaire
change in level of responsibility at work. Normal or
elevated LDH status were based on local laboratory
assessments. For patient-reported outcomes, mean
changes from baseline in assessment points throughout
the study were evaluated for all treatment cohorts.
Results
Patient characteristics and treatment patterns
Among 1356 patients prospectively enrolled in this
study, 1094 (81%) received ipilimumab and 262 (19%)
received non-ipilimumab treatment as index therapy
(Fig. 1). In the overall population, median age was 64
years, 60% of patients were male, 78% were from Europe,
78% had received previous treatment with systemic ther-
apy for advanced melanoma, 47% had stage IV M1C dis-
ease, and 21% had CNS metastases (Table 1). Although
pretreatment LDH and ECOG PS data were not assessed
or missing in a substantial proportion of patients, 39% of
patients had elevated LDH and 6% had ECOG PS ≥ 2
(Table 1). Among patients treated with ipilimumab ther-
apy at any time during the study period (n = 1151), 719
(62%) received 4 doses (Additional file 1: Table A.2);
patients received 2.5 to 3.5 mg/kg of ipilimumab, con-
sistent with the recommended dose of 3 mg/kg.
In the ipilimumab-treated cohort, 780 (71%) patients
did not receive subsequent therapy (IPI-noOther) and
314 (29%) received subsequent non-ipilimumab therapy
(IPI-Other) during the study period. In the non-
ipilimumab–treated cohort, 205 (78%) patients remained
on the same non-ipilimumab therapy or received other
non-ipilimumab therapy (Other-Other) and 57 (22%)
received subsequent ipilimumab therapy (Other-IPI)
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Table 1 Patient demographics and baseline characteristics for all prospective patients based on index therapy
All prospective
patients (N = 1356)









Median age, years (range) 64 (22–90) 65 (22–90) 62 (25–88) 63 (24–89) 60 (27–84)
Sex, no. (%)
Male 819 (60) 483 (62) 178 (57) 118 (58) 40 (70)
Female 537 (40) 297 (38) 136 (43) 87 (42) 17 (30)
Race, no. (%)
White 1300 (96) 746 (96) 300 (96) 200 (98) 54 (95)
Asian 3 (< 1) 2 (< 1) 0 0 1 (2)
Other 7 (1) 6 (1) 1 (< 1) 0 0
Not specified 46 (3) 26 (3) 13 (4) 5 (2) 2 (4)
Geographic region, no. (%)
Europe 1061 (78) 641 (82) 231 (74) 149 (73) 40 (70)
North America 170 (13) 67 (9) 64 (20) 29 (14) 10 (18)
Rest of world 125 (9) 72 (9) 19 (6) 27 (13) 7 (12)
Time on study,a months
Mean (SD) 10 (11) 9 (10) 14 (11) 9 (10) 13 (9)
Median (range) 6 (0–50) 5 (0–46) 10 (1–39) 5 (0–38) 9 (2–50)
Previous systemic therapy for advanced melanoma, no. (%)
Yes 1064 (78) 619 (79) 233 (74) 169 (82) 43 (75)
No 292 (22) 161 (21) 81 (26) 36 (18) 14 (25)
BRAF mutation status, no. (%)
Mutant 542 (40) 262 (34) 135 (43) 116 (57) 29 (51)
Wild-type 743 (55) 471 (60) 162 (52) 84 (41) 26 (46)
Inconclusive/unknown 12 (1) 8 (1) 3 (1) 1 (< 1) 0
Missing 59 (4) 39 (5) 14 (4) 4 (2) 2 (4)
ECOG PS, no. (%)
0 470 (35) 274 (35) 134 (43) 47 (23) 15 (26)
1 328 (24) 208 (27) 59 (19) 48 (23) 13 (23)
2 63 (5) 35 (4) 5 (2) 22 (11) 1 (2)
3 13 (1) 3 (< 1) 0 8 (4) 2 (4)
4 2 (< 1) 1 (< 1) 0 1 (< 1) 0
Missing 480 (35) 259 (33) 116 (37) 79 (39) 26 (46)
Disease stage, no. (%)
Stage III 44 (3) 26 (3) 10 (3) 3 (1) 5 (9)
Stage IV 1312 (97) 754 (97) 304 (97) 202 (99) 52 (91)
Metastases stage, no. (%)
M0 43 (3) 25 (3) 10 (3) 3 (1) 5 (9)
M1a 150 (11) 85 (11) 41 (13) 22 (11) 2 (4)
M1b 247 (18) 144 (18) 69 (22) 29 (14) 5 (9)
M1c 638 (47) 382 (49) 143 (46) 85 (41) 28 (49)
CNS 278 (21) 144 (18) 51 (16) 66 (32) 17 (30)
CNS metastases,b no. (%)
Symptomatic 85 (31) 42 (29) 16 (31) 22 (33) 5 (29)
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during the study period (Fig. 1). Overall, subsequent
systemic therapy was received by 313 of 1094 (29%)
patients in the ipilimumab-treated cohort and 111 of
262 (42%) patients in the non-ipilimumab–treated co-
hort (Table 2). The most common systemic therapy was
anti–PD-1 treatment (51%) in the IPI-Other group and
chemotherapy (16%) in the Other-Other group.
Safety
Safety was assessed in patients who had received the
first dose of ipilimumab at any time during the study
period as index therapy or subsequent therapy (IPI-
noOther, IPI-Other, and Other-IPI; n = 1151). TRAEs
of any grade and of grade ≥ 3 were reported in 66%
(756 of 1151) and 26% (296 of 1151) of patients,
respectively (Table 3). Early-onset TRAEs of any
grade were reported in 64% (734 of 1151) of patients,
and grade ≥ 3 events were reported in 24% (275 of
1151) of patients. Among those who were followed
post-treatment, late-onset TRAEs of any grade were
reported in 20% (128 of 653) of patients and were
grade ≥ 3 in 6% (42 of 653) of patients. The majority
of TRAEs were consistent with the mechanism of ac-
tion of ipilimumab; the most common any-grade
TRAEs were diarrhoea (21%), fatigue (16%), rash
(12%), and nausea (10%) (Additional file 1: Table
A.3). TRAEs or serious adverse events that led to
death were reported in 22 patients; of these, 10 were
attributed to immune-related adverse events. For
many of these reported deaths, the cause was also
Table 1 Patient demographics and baseline characteristics for all prospective patients based on index therapy (Continued)
All prospective
patients (N = 1356)









Asymptomatic 193 (69) 102 (71) 35 (69) 44 (67) 12 (71)
LDH status at study entry, no. (%)
Normal 542 (40) 298 (38) 159 (51) 64 (31) 21 (37)
Elevated or outside of normal 531 (39) 310 (40) 105 (33) 92 (45) 24 (42)
Not assessed 283 (21) 172 (22) 50 (16) 49 (24) 12 (21)
CNS central nervous system, ECOG PS Eastern Cooperative Oncology Group performance status, IPI ipilimumab, LDH lactate dehydrogenase, SD standard deviation.
aDefined as the time from study completion/discontinuation/death/data cut date (whichever came first) − the index therapy date + 1; study time for a patient may
have exceeded 1065 days
bThe number of patients who reported the CNS as the site of distant metastasis was used as the denominator
Table 2 Subsequent therapies
IPI-treated cohort Non-IPI–treated cohort
IPI-noOther (n = 780)a IPI-Other (n = 314) Other-Other (n = 205) Other-IPI (n = 57)
Systemic therapy, no. (%) 0 313 (100) 54 (26) 57 (100)
Immunotherapy 0 181 (58) 18 (9) 57 (100)
Anti–PD-1 agentb 0 161 (51) 18 (9) 10 (18)
Anti–CTLA-4 agentc 0 34 (11) 0 57 (100)
Other systemic therapy, no. (%) 0 186 (59) 43 (21) 15 (26)
BRAF ± MEK inhibitord 0 103 (33) 18 (9) 8 (14)
Chemotherapye 0 110 (35) 33 (16) 12 (21)
Other investigational agentf 0 11 (4) 1 (<1) 0
Otherg 0 11 (4) 0 0
Radiotherapyh 138 (18) 101 (32) 21 (10) 16 (28)
CTLA-4 cytotoxic T-lymphocyte antigen 4, IPI ipilimumab, PD-1 programmed death 1.
aRadiotherapy was allowed with ipilimumab in this cohort; therefore, it was not considered subsequent therapy
bPembrolizumab or nivolumab
cIpilimumab
dDabrafenib ± trametinib or vemurafenib ± cobimetinib
eBleomycin, carboplatin, cisplatin, combinations of antineoplastic agents, cyclophosphamide, dacarbazine, dactinomycin, docetaxel, etoposide, fotemustine,
gemcitabine, lomustine, melphalan, paclitaxel, paclitaxel + carboplatin, temozolomide, treosulfan, trofosfamide, vinblastine, vincristine, vindesine, or vinorelbine
fBevacizumab or imatinib
gAldesleukin, antineoplastic and immunomodulating agents, interferon-alpha, interleukin-2, melanoma vaccine, other therapeutic products, or
monoclonal antibodies
hRadiation, radiosurgery, radiotherapy, or yttrium (90Y)
Dalle et al. BMC Cancer          (2021) 21:642 Page 6 of 12
listed as “succumbed to melanoma” or as unknown;
therefore, whether these deaths were due to TRAEs
or whether the adverse events were ongoing at the
time of death, but not the direct cause, is unclear.
Immune-related adverse events of any grade and
grade ≥ 3 were reported in 49 and 19% of patients, re-
spectively (Additional file 1: Table A.4). Overall, the
incidence of grade ≥ 3 ipilimumab-related adverse
events was higher in the first year compared with
subsequent years after ipilimumab treatment initiation
(Additional file 1: Table A.5).
Effectiveness
The 3-year OS rate was 28% in the ipilimumab-treated
cohort and 25% in the non-ipilimumab–treated cohort
(Additional file 1: Fig. A.2). In a multivariate model in
which the reference subgroup was IPI-noOther, the
hazard ratio was 0.57 (95% CI 0.47 to 0.68; p<0.001) for
Table 3 Summary of adverse events using CTCAE criteria
All IPI-treated patientsa
On studyb (n = 1151) Early onsetc (n = 1151) Late onsetd (n = 653)
Any treatment-related adverse event, no. (%)
Any grade 756 (66) 734 (64) 128 (20)
Grade≥ 3 296 (26) 275 (24) 42 (6)
Serious adverse event 225 (20) 218 (19) 15 (2)
Immune-related adverse event, no. (%)
Any grade 569 (49) 550 (48) 65 (10)
Grade≥ 3 211 (19) 211 (18) 20 (3)
Treatment-related adverse event/serious adverse event leading to discontinuation, no. (%)
Any grade 158 (14) 148 (13) 14 (2)
Grade≥ 3 102 (9) 99 (9) 4 (1)
Treatment-related adverse event/serious adverse event leading to death,e no. (%)
Any grade 22 (2) 21 (2) 1 (<1)
Grade≥ 3 17 (1) 16 (1) 1 (<1)
CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events, IPI, ipilimumab.
aIncludes patients who received ipilimumab therapy at any time during the study period (IPI-noOther, IPI-Other, Other-IPI)
bFrom first dose of ipilimumab until discontinuation from study or end of study, whichever came first
cOccurring between the first dose and 90 days after the last dose of ipilimumab therapy
dOccurring 90 days after the last dose of ipilimumab; the denominator is the number of ipilimumab-treated patients who were in the post-treatment phase
of follow-up
e10 deaths were attributed to immune-related adverse events
Fig. 2 OS in the ipilimumab-treated and non-ipilimumab treated cohorts. IPI ipilimumab, OS overall survival
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IPI-Other, 1.01 (95% CI 0.83 to 1.23; P = 0.897) for
Other-Other, and 0.73 (95% CI 0.53 to 1.01; P = 0.061)
for Other-IPI (Fig. 2). Patients in the IPI-Other group
had a 43% reduced risk of death compared with those in
the IPI-noOther group. Among the treatment sub-
groups, ipilimumab-treated and non-ipilimumab–treated
patients who switched therapy (IPI-Other and Other-
IPI) had longer OS than those who did not switch
therapy (IPI-noOther and Other-Other). Patients in the
IPI-Other group tended to have longer OS than those in
the Other-IPI group (Fig. 2).
In previously treated patients (n = 1064), 3-year OS
rates were 25% in the ipilimumab-treated cohort and
22% in the non-ipilimumab–treated cohort; the OS
rates among treatment-naive patients (n = 292) were
40 and 33%, respectively (Additional file 1: Fig. A.3).
In multivariate models comparing the four subgroups,
the IPI-noOther group was considered the reference
subgroup. For previously treated patients, the hazard
ratio was 0.53 (95% CI 0.43 to 0.65; P < 0.001) for
IPI-Other, 0.98 (95% CI 0.80 to 1.21; P = 0.882) for
Other-Other, and 0.68 (95% CI 0.47 to 0.99; P =
0.045) for Other-IPI (Fig. 3a). Patients with prior
therapy who did not switch therapy (IPI-noOther and
Other-Other) showed similar OS. For treatment-naive
patients, the hazard ratio was 0.77 (95% CI 0.51 to
1.16; P = 0.219) for IPI-Other, 1.21 (95% CI 0.72 to
2.01; P = 0.473) for Other-Other, and 1.04 (95% CI
0.50 to 2.15; P = 0.926) for Other-IPI (Fig. 3b). Pa-
tients in the IPI-noOther group had a 21% reduced
risk of death (not significant) compared with those in
the Other-Other group.
Disease control rates (the sum of the rates for complete
response, partial response, and stable disease) were 16%
for IPI-noOther, 20% for IPI-Other, 16% for Other-Other,
and 7% for Other-IPI (Additional file 1: Table A.6).
Quality of life
In the overall patient population, completion rates for
EORTC QLQ-C30 global health status were between 58
and 80% (Additional file 1: Table A.7). On treatment,
there were no major differences between the four
subgroups in mean changes from baseline for EORTC
QLQ-C30 global health status (Fig. 4). Among surviving
patients in all treatment groups, initial global health
status changes from baseline were mostly negative
(indicating deterioration) until approximately year 2 and
became positive (indicating improvement) by year 3.
Notable exceptions were observed in IPI-noOther group,
in which patients showed improvement by the end of
year 1, and for Other-Other group, in which patients did
not show deterioration until the end of year 1. Numeric-
ally, the three symptom scales (fatigue, nausea and
vomiting, and pain), six single-item symptom scores
(dyspnea, insomnia, appetite loss, constipation, diarrhea,
and financial difficulties), and four of the five functional
scales (physical, role, cognitive, and social) generally
showed either no change or deterioration from baseline
early in the study. Improvement by the end of year 3 re-
sulted in changes that were not clinically meaningful
(Additional file 1: Fig. A.4a–m). However, the emotional
functional scale showed primarily positive changes (indi-
cating improvement) throughout the study (Additional
file 1: Fig. A.4n).
Discussion
This prospective real-world study presents long-term
outcomes (≥ 3 years of follow-up) of patients with ad-
vanced melanoma treated with ipilimumab and other
therapies. Safety outcomes and OS in patients treated
with ipilimumab 3mg/kg were similar to those previ-
ously reported in ipilimumab randomised clinical trials,
despite the inclusion of patients who are typically
Fig. 3 OS in previously treated a and treatment-naive b patients in ipilimumab-treated and non-ipilimumab–treated cohorts.
IPI ipilimumab, OS overall survival
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excluded from randomised controlled trials (e.g., those
with ECOG PS ≥ 2 or active/untreated brain metastases)
[12, 13]. This study also showed that patients who
switched therapy (from ipilimumab or non-ipilimumab
therapies) had longer OS than those who did not switch
therapy. QoL did not deteriorate significantly over the
study period in either treatment cohort.
The patient population in the IMAGE study was
broadly comparable to those reported in ipilimumab
randomised clinical trials [4–6], and other real-world
studies [21, 22]. The types, incidence, and severity of
all adverse events associated with ipilimumab were
similar to those previously reported in patients with
advanced melanoma. No new safety signals were iden-
tified. In phase III trials, TRAEs of any grade and
grade ≥ 3 were reported in 63 to 80% and 18 to 23%
of patients treated with ipilimumab 3 mg/kg, respect-
ively [4, 6]; in the current study these rates were 66 and
26%, respectively, mostly immune-related. Even though
66% of patients experienced TRAEs, most (62%) were able
to complete the four recommended infusions of
ipilimumab.
The proportion of ipilimumab-treated patients who re-
ceived subsequent systemic therapy (29%) in this study
was lower than that observed in a phase III clinical trial
comparing different doses of ipilimumab (38%) [6], per-
haps due to differences between the real-world popula-
tion included in the current study and those included in
clinical trials with stringent entry criteria or differences
in the availability of subsequent therapies at the time
when these studies were conducted. In the current study,
a higher proportion of patients in the non-ipilimumab–
treated cohort received subsequent systemic therapy
than those in the ipilimumab-treated cohort (42% vs.
29%). Recent trials have shown that a higher frequency
of subsequent treatment use is associated with less
efficacious initial therapy [14, 23].
OS results from the current study were consistent
with those observed in prospective clinical trials of
patients with advanced melanoma receiving ipilimu-
mab. In a pooled analysis, the 3-year OS rate was
22% for all patients, 20% for previously treated pa-
tients, and 26% for treatment-naive patients [11]; in
the IMAGE study these rates were 28, 25, and 40%,
respectively. The higher OS rates in the current study
may be attributed to the changing treatment land-
scape for advanced melanoma, which evolved rapidly
during the period in which this study was conducted
(2012 to 2015). Initially, ipilimumab was the only ap-
proved immune checkpoint inhibitor that was avail-
able for treatment of patients with advanced
melanoma. Subsequently, dabrafenib (targeted ther-
apy) was approved in 2013, and pembrolizumab and
nivolumab (anti–PD-1 agents) were approved in 2014,
becoming available for use as subsequent therapies.
Availability of these newer agents may have contrib-
uted to longer OS in patients who switched from ipi-
limumab or non-ipilimumab therapy than those who
did not switch therapy. Similar improvements in OS
were observed in prospective trials in which patients
Fig. 4 Mean changes from baseline on treatment for EORTC QLQ-C30 global health status. EORTC European Organisation for Research and
Treatment of Cancer, IPI ipilimumab, QLQ-C30 Core Quality of Life Questionnaire, SE standard error
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who had disease progression after ipilimumab therapy
received subsequent anti–PD-1 treatment [24, 25]. Of
note, OS in the IMAGE study was similar between
the IPI-Other and Other-IPI cohorts, and OS was
longer in both of those cohorts than in the IPI-
noOther and the Other-Other cohorts, suggesting that
the use of immune checkpoint inhibitor therapy in se-
quence with other therapies may provide superior
survival outcomes compared with other regimens.
The potential residual effect of immortal time bias
(also known as survival treatment selection bias)
should be considered in interpreting the magnitude of
difference in OS between cohorts in which patients
switched or did not switch therapy.
Although the treatment paradigm for metastatic
melanoma has shifted with the use of anti–PD-1
checkpoint inhibitors alone or in combination with
ipilimumab, ipilimumab monotherapy may still be a
consideration, such as in the treatment of particular
patient subgroups following failure of anti–PD-1 ther-
apy [14]. Some clinical trials have shown that ipilimu-
mab has antitumour activity in patients who had
disease progression on anti–PD-1 therapy and re-
ceived subsequent ipilimumab [26, 27]. In the current
study, patients in the Other-IPI group tended to have
longer survival than those in the Other-Other group.
Descriptive OS analysis of patients who were previ-
ously treated and those who were treatment-naive
suggested a beneficial role for ipilimumab as first-line
treatment for patients with advanced melanoma in an
era when anti–PD-1 therapies were not available.
During 3 or more years of follow-up, no major dif-
ferences in QoL outcomes were observed between the
four ipilimumab and non-ipilimumab–treated cohorts.
This observation is consistent with the results re-
ported in a phase 3 clinical trial in patients with ad-
vanced melanoma in which ipilimumab did not have
a significant negative impact on health-related QoL
during the treatment induction phase [28]; however,
long-term QoL results were not available for that
trial. Although the current analysis did show initial
deterioration in global health status (with improve-
ment by year 3), these findings are difficult to correl-
ate with disease progression, toxicities, or other
clinical outcomes and would benefit from further re-
search. There was no change or deterioration from
baseline in most of the QLQ-C30 components (three
symptom scales, six single-item symptom scores, and
four of five functional scale scores [physical, role,
cognitive, and social]), with improvements by the end
of year 3. However, these results should be inter-
preted with caution as patients who completed the
questionnaires were more likely to have been doing
better than those who did not; moreover, the cohorts
that started with a non-ipilimumab treatment had
considerably fewer patients than the ipilimumab-
treated cohorts.
This study had limitations, largely those inherent to
a real-world study, that should be considered in inter-
preting the findings. Data were limited in a number
of clinical characteristic categories because of incom-
plete patient information. For example, ECOG PS was
missing for 33 to 46% of patients, LDH status was
not assessed in 16 to 24% of patients, and BRAF sta-
tus was unknown for 2 to 6% of patients. In addition,
the patient population was not uniform between the
study cohorts because of the non-randomised nature
of the study. For example, more patients had central
nervous system metastasis in the non-ipilimumab–
treated cohort (30 to 32%) than in the ipilimumab-
treated cohort (16 to 18%).
Conclusions
Long-term, real-world safety and effectiveness in the
IMAGE study were consistent with safety and efficacy
in ipilimumab clinical trials. OS analysis across previ-
ously treated and treatment-naive patients suggested a
beneficial role of ipilimumab early in the disease, with
no detrimental impact on QoL. Although ipilimumab
is no longer commonly used as first-line monotherapy
for patients with advanced melanoma, the results of
this study provide reassurance that patients who
switch to ipilimumab still gain benefit and that the
safety profile of the drug in clinical trials is not sig-
nificantly different in real-world clinical practice.
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